2026-10-09 日报 · BioAI 日知
北京时间 08:00 汇总前 24 小时新入库原文的冻结选集，最多 100 条。公开范围与来源验证在阅读时复核。
当前公开 93 条；窗口 Thu Oct 08 2026 00:00:00 GMT+0000 (Coordinated Universal Time) 至 Fri Oct 09 2026 00:00:00 GMT+0000 (Coordinated Universal Time)。来源发布日期与本站收录时间分别保留，选集不是全部行业新闻。
Owkin to Integrate Kognitic's Clinical Trial Data Into K Pro Through New Collaboration
Owkin official newsroom · 行业原文收录 · 来源发布：Thu Aug 06 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:09:24 GMT+0000 (Coordinated Universal Time)
NEW YORK & PARIS — Owkin, the agentic AI company pioneering Biological Artificial SuperIntelligence to revolutionize drug discovery and development, today announced a data collaboration with Kognitic to integrate Kogniti
Isomorphic Labs announces $600m external investment round
Isomorphic Labs official announcements · 行业原文收录 · 来源发布：Mon Mar 31 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:09:23 GMT+0000 (Coordinated Universal Time)
Listen: Spotify Apple Podcasts Isomorphic Labs announces it has raised $600 Million in its first external funding round. The financing round is led by Thrive Capital, with participation from GV, and follow-on capital fro
Owkin and CRO Aviano Sign Master Partnership Agreement to Foster Collaborative Oncology Research
Owkin official newsroom · 行业原文收录 · 来源发布：Fri Aug 07 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:09:15 GMT+0000 (Coordinated Universal Time)
PARIS & PORDENONE, Italy — Owkin, the agentic AI company pioneering the first autonomous AI scientist to revolutionize drug discovery and development, and the Centro di Riferimento Oncologico di Aviano (CRO), a leading I
Isomorphic Labs appoints Dr. Ben Wolf as Chief Medical Officer and establishes US Presence
Isomorphic Labs official announcements · 行业原文收录 · 来源发布：Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:09:05 GMT+0000 (Coordinated Universal Time)
Listen: Spotify Apple Podcasts Isomorphic Labs appoints Dr. Ben Wolf M.D., Ph.D., as Chief Medical Officer and establishes US Presence. Dr. Wolf will be based in the company's newly established Cambridge location, where
Owkin to License K Pro AI Scientist and Multimodal Oncology and Immunology Data to Boehringer Ingelheim
Owkin official newsroom · 行业原文收录 · 来源发布：Wed Sep 02 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:56 GMT+0000 (Coordinated Universal Time)
NEW YORK & PARIS — Owkin, the agentic AI company striving to transform drug discovery and development for biopharma, today announced a license agreement with Boehringer Ingelheim for K Pro, Owkin’s AI Scientist, together
Isomorphic Labs to appoint Max Jaderberg as President
Isomorphic Labs official announcements · 行业原文收录 · 来源发布：Wed Nov 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:54 GMT+0000 (Coordinated Universal Time)
Listen: Spotify Apple Podcasts Isomorphic Labs announces the appointment of Max Jaderberg as President of the company effective 1 January 2026, transitioning from his current role as Isomorphic Labs’ Chief AI Officer. Co
Owkin to License K Pro and Multimodal Data to Servier to Advance Oncology Research
Owkin official newsroom · 行业原文收录 · 来源发布：Fri Sep 11 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:48 GMT+0000 (Coordinated Universal Time)
NEW YORK & PARIS - September 11, 2026 — Owkin, the agentic AI company pioneering the first automated AI scientist to revolutionize drug discovery and development, today announced an agreement with Servier, an independent
Iambic Named to CNBC Disruptor 50 for Second Consecutive Year
Iambic official newsroom · 行业原文收录 · 来源发布：Tue May 19 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:47 GMT+0000 (Coordinated Universal Time)
San Diego, CA – May 19, 2026 – Iambic is a CNBC Disruptor 50 for the second year in a row, joining the ranks of repeat Disruptors OpenAI, AirBnB, and SpaceX. The Disruptor 50 is an annual list curated by CNBC to recogniz
Isomorphic Labs Enters into a Research Collaboration with Johnson & Johnson
Isomorphic Labs official announcements · 行业原文收录 · 来源发布：Tue Jan 20 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:46 GMT+0000 (Coordinated Universal Time)
Listen: Spotify Apple Podcasts Isomorphic Labs announces a cross-modality, multi-target research collaboration with Johnson & Johnson. This partnership brings together Iso’s AI-first approach to drug discovery with Johns
Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement with AstraZeneca
Owkin official newsroom · 行业原文收录 · 来源发布：Wed May 13 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:37 GMT+0000 (Coordinated Universal Time)
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to revolutionize drug discovery and development, today announced an agreement with AstraZeneca to build biopharma agents as part of their t
Bayer and Iambic collaborate to advance drug discovery with AI
Iambic official newsroom · 行业原文收录 · 来源发布：Mon Jun 22 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:35 GMT+0000 (Coordinated Universal Time)
Bayer and Iambic collaborate to advance drug discovery with AI Collaboration focuses on small molecule discovery Bayer to leverage Iambic’s AI platform to address hard-to-drug targets Collaboration will strengthen Bayer’
Isomorphic Labs announces Series B investment round
Isomorphic Labs official announcements · 行业原文收录 · 来源发布：Tue May 12 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:33 GMT+0000 (Coordinated Universal Time)
Listen: Spotify Apple Podcasts Isomorphic Labs announces it has raised $2.1 Billion in Series B funding. The financing round is led by Thrive Capital, and includes participation from existing backers Alphabet and GV alon
Owkin and BeOne Medicines Sign Clinical Supply Agreement for Tislelizumab in INVOKE Trial of OKN4395
Owkin official newsroom · 行业原文收录 · 来源发布：Mon Jun 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:24 GMT+0000 (Coordinated Universal Time)
BeOne Medicines will supply tislelizumab, its PD-1 inhibitor, to Owkin's ongoing INVOKE Phase 1a/1b trial of OKN4395 in patients with advanced solid tumors (NCT06789172). The agreement opens a combination arm pairing OKN
AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery
Iambic official newsroom · 行业原文收录 · 来源发布：Mon Sep 21 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:23 GMT+0000 (Coordinated Universal Time)
− Multi-year partnership applies Iambic’s AI platform to speed up small molecule drug discovery in immunology, neuroscience and oncology − Companies to pursue programs with both first-in-class and best-in-class potential
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi
Owkin official newsroom · 行业原文收录 · 来源发布：Fri Jun 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:10 GMT+0000 (Coordinated Universal Time)
NEW YORK & PARIS - 5th June, 2026 - Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to
Iambic Launches Enchant v3 – Molecular Superintelligence Designed to Advance End-to-End Drug Discovery & Development
Iambic official newsroom · 行业原文收录 · 来源发布：Mon Sep 21 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:09 GMT+0000 (Coordinated Universal Time)
Enchant v3 is the next generation of Iambic’s multimodal transformer model, trained using 41 billion parameters on more than 6,000 molecular properties across 16 biomedical data modalities Enchant v3 ingests diverse data
Building a new path to make medicines with AI
Isomorphic Labs official announcements · 行业原文收录 · 来源发布：Tue Sep 29 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:09 GMT+0000 (Coordinated Universal Time)
Listen: Spotify Apple Podcasts The Scale Solving all disease is one of the most monumentally complex challenges in science. Today, for the first time, AI provides the foundation to make it achievable. Tackling the fronti
Estonia and Owkin Partner to Advance Sovereign AI in Biology
Owkin official newsroom · 行业原文收录 · 来源发布：Tue Sep 29 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:00 GMT+0000 (Coordinated Universal Time)
Tallinn / Paris, 29 September 2026 – Estonia, led by the National Applied Research Center Metrosert, and Owkin today announced a collaboration to advance sovereign AI in biological and health research, working with Metro
Iambic Submits IND for a Potentially Brain-Penetrant KIF18A Inhibitor IAM217, Its Second Wholly Owned AI-Discovered Candidate
Iambic official newsroom · 行业原文收录 · 来源发布：Mon Oct 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:07:58 GMT+0000 (Coordinated Universal Time)
In nonclinical studies, IAM217 was observed to have potent and selective target engagement with a favorable drug-drug interaction profile IAM217 is believed to be brain penetrant, producing regression of established intr
Isomorphic Labs joins the Virtual Biology Initiative to build foundational data for AI models to predict and treat disease
Isomorphic Labs official announcements · 行业原文收录 · 来源发布：Wed Oct 07 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:07:57 GMT+0000 (Coordinated Universal Time)
Listen: Spotify Apple Podcasts Convened by Biohub, participating organisations are investing funding, data, computation and new measurement technology - the largest coordinated commitment to generating AI-ready biologica
Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program
Recursion official investor newsroom · 行业原文收录 · 来源发布：Wed Aug 05 2026 10:30:38 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:07:50 GMT+0000 (Coordinated Universal Time)
Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program August 5, 2026 at 6:30 AM EDT PDF Version Genentech advanced the collaboration's first neurosci
Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian Cancer
Generate Biomedicines official news-release RSS · 行业原文收录 · 来源发布：Thu Oct 01 2026 11:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:07:27 GMT+0000 (Coordinated Universal Time)
Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation cell therapy for ovarian cancer to enter clinical trials First patient treated in new clinical trial underway at Roswel
Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma Engineered with AI
Generate Biomedicines official news-release RSS · 行业原文收录 · 来源发布：Mon Dec 01 2025 10:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:07:27 GMT+0000 (Coordinated Universal Time)
SOLAIRIA‑1 and SOLAIRIA‑2 will evaluate GB-0895 in approximately 1,600 patients with severe asthma whose disease remains inadequately controlled on current therapies These are the first global Phase 3 studies of a long-a
Generate:Biomedicines to Present Phase 1 Results for AI-Engineered GB-0895 in Asthma at the European Respiratory Society International Congress
Generate Biomedicines official news-release RSS · 行业原文收录 · 来源发布：Thu Sep 25 2025 11:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:07:27 GMT+0000 (Coordinated Universal Time)
GB-0895, a next-generation, ultra-high affinity anti-TSLP monoclonal antibody, demonstrated prolonged half-life and sustained pharmacology in asthma patients GB-0895 is optimized for a single subcutaneous injection every
Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering
Generate Biomedicines official news-release RSS · 行业原文收录 · 来源发布：Thu Feb 26 2026 23:11:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:07:27 GMT+0000 (Coordinated Universal Time)
SOMERVILLE, Mass., February 26, 2026 — Generate Biomedicines, Inc. (Nasdaq: GENB) (“Generate”), a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development, t
Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
Absci official news RSS · 行业原文收录 · 来源发布：Thu Sep 24 2026 12:00:49 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:07:26 GMT+0000 (Coordinated Universal Time)
Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial in mid-2027 VANCOUVER
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)
Absci official news RSS · 行业原文收录 · 来源发布：Wed Jun 24 2026 10:30:27 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:07:26 GMT+0000 (Coordinated Universal Time)
Study medication appears well tolerated, with favorable safety data across all blinded single ascending dose (SAD) cohorts Estimated half-life of at least 65 days supports potential for ABS-201 targeted dosing interval o
Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026
Absci official news RSS · 行业原文收录 · 来源发布：Tue Jul 14 2026 20:05:30 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:07:26 GMT+0000 (Coordinated Universal Time)
VANCOUVER, Wash. and NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announc
Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026
Absci official news RSS · 行业原文收录 · 来源发布：Thu Apr 23 2026 20:04:58 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:07:26 GMT+0000 (Coordinated Universal Time)
VANCOUVER, Wash. and NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announ
NVIDIA BioNeMo Platform Adopted by Life Sciences Leaders to Accelerate AI-Driven Drug Discovery
NVIDIA Healthcare and Life Sciences official RSS · 行业原文收录 · 来源发布：Mon Jan 12 2026 15:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:07:24 GMT+0000 (Coordinated Universal Time)
NVIDIA BioNeMo Platform Adopted by Life Sciences Leaders to Accelerate AI-Driven Drug Discovery
NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery in the Age of AI
NVIDIA Healthcare and Life Sciences official RSS · 行业原文收录 · 来源发布：Mon Jan 12 2026 15:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:07:24 GMT+0000 (Coordinated Universal Time)
NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery in the Age of AI
NVIDIA Healthcare Launches Generative AI Microservices to Advance Drug Discovery, MedTech and Digital Health
NVIDIA Healthcare and Life Sciences official RSS · 行业原文收录 · 来源发布：Mon Mar 18 2024 21:16:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:07:24 GMT+0000 (Coordinated Universal Time)
NVIDIA Healthcare Launches Generative AI Microservices to Advance Drug Discovery, MedTech and Digital Health
Isomorphic Labs secures $2.1 Billion funding to scale its AI drug design engine
Isomorphic Labs official announcements · 行业原文收录 · 来源发布：Tue May 12 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 08:27:55 GMT+0000 (Coordinated Universal Time)
Isomorphic Labs secures $2.1 Billion funding to scale its AI drug design engine an AI-first drug design and development company, today announced it has raised $2.1 Billion in Series B funding
活性提升超千倍！晶泰分子胶管线公布最新进展
XtalPi official Chinese RSS · 行业原文收录 · 来源发布：Tue Oct 06 2026 03:29:09 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 08:23:52 GMT+0000 (Coordinated Universal Time)
活性提升超千倍！晶泰分子胶管线公布最新进展 并结合计算和实验数据训练 AI 模型，对不同 E3-目标蛋白组合进行优先级判断。
Insights into the AVA™ Emulation System: Ushering in a New Era of Human-Relevant Drug Discovery
Emulate official blog RSS · 行业原文收录 · 来源发布：Wed Aug 27 2025 20:53:46 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 07:04:42 GMT+0000 (Coordinated Universal Time)
By Jim Corbett, CEO, Emulate Drug discovery is at a crossroads. With nearly 90% of clinical trial candidates failing to reach FDA approval, the need for more predictive, human-relevant models has never been greater. That
HUB Organoids Announces New Corporate Strategy and Completes Transition from Foundation to Private Company
HUB Organoids official news RSS · 行业原文收录 · 来源发布：Tue Jul 18 2023 01:00:54 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 07:03:32 GMT+0000 (Coordinated Universal Time)
[Utrecht, July 18 2023] — HUB Organoids (HUB), the global leader in the field of patient-derived organoids, is excited to announce a significant milestone in its evolution. After years of successful operations as a found
The Life Science business of Merck KGaA, Darmstadt, Germany, to Acquire HUB Organoids Holding B.V., Advancing Next Generation Biology Portfolio
HUB Organoids official news RSS · 行业原文收录 · 来源发布：Tue Dec 17 2024 14:05:21 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 07:03:32 GMT+0000 (Coordinated Universal Time)
HUB internationally recognized pioneer in organoid development Acquisition expands Merck’s 2D and 3D cell culture portfolio Organoids part of fastest growing cell culture segment; hold potential to speed up drug developm
Imagine reducing the time to identify a drug that shows results in the clinic to five years: this proof-of-concept study shows how
HUB Organoids official news RSS · 行业原文收录 · 来源发布：Sat Mar 04 2023 01:56:32 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 07:03:32 GMT+0000 (Coordinated Universal Time)
Patients with mutated KRAS (Kirsten rat sarcoma virus) gene account for around 30-50% of the population with colorectal cancer (CRC) and do not respond to cetuximab, a recognized choice of antibody therapy. A new proof-o
FDA Modernization Act 2.0: We welcome the dawn of an organoid era
HUB Organoids official news RSS · 行业原文收录 · 来源发布：Sat Mar 04 2023 13:32:25 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 07:03:32 GMT+0000 (Coordinated Universal Time)
The post FDA Modernization Act 2.0: We welcome the dawn of an organoid era appeared first on HUB Organoids .
Tumors in Space Investigates Microgravity’s Impact on Cancer Using Patient-Derived HUB Organoids
HUB Organoids official news RSS · 行业原文收录 · 来源发布：Thu Nov 30 2023 09:42:03 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 07:03:32 GMT+0000 (Coordinated Universal Time)
Utrecht, November 30, 2023 – HUB Organoids B.V. participates in the second Tumors in Space European Space Agency parabolic flight which investigates the effect of microgravity on gene expression to identify potential tar
HUB Organoids Launches IntegriGut Screen: A Breakthrough Service Offering for Inflammatory Bowel Disease (IBD) Drug Discovery and Development
HUB Organoids official news RSS · 行业原文收录 · 来源发布：Wed Jan 24 2024 17:36:01 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 07:03:32 GMT+0000 (Coordinated Universal Time)
Utrecht, Netherlands – 25th Jan 2024 – HUB Organoids (HUB), a global leader and sole proprietor of patient-derived organoid technology for drug discovery and development, today announced the global launch of its new Inte
HUB Organoids B.V. Awarded Frost & Sullivan’s 2024 Technology Innovation Leadership Award for Transforming Drug Development with Highly Advanced Organoid Technology
HUB Organoids official news RSS · 行业原文收录 · 来源发布：Tue May 14 2024 12:51:39 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 07:03:32 GMT+0000 (Coordinated Universal Time)
HUB Organoids B.V. revolutionizes preclinical and clinical drug development through its cutting-edge organoid technology, enhancing its accuracy and efficiency. San Antonio, TX — May 14 2024 — Frost & Sullivan recently r
HUB Organoids extends partnership with Molecular Devices to advance automated intestinal organoid screening technology
HUB Organoids official news RSS · 行业原文收录 · 来源发布：Sat Mar 04 2023 13:34:09 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 07:03:32 GMT+0000 (Coordinated Universal Time)
SAN JOSE, Calif., and UTRECHT, Netherlands, Feb. 13, 2023 – Molecular Devices, LLC., a leading provider of high-performance life science solutions, and HUB Organoids (HUB), the pioneer in the field of adult stem cell-der
HUB Organoids take their first parabolic flight!
HUB Organoids official news RSS · 行业原文收录 · 来源发布：Sat Mar 04 2023 13:32:53 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 07:03:32 GMT+0000 (Coordinated Universal Time)
The post HUB Organoids take their first parabolic flight! appeared first on HUB Organoids .
The Life Science business of Merck KGaA, Darmstadt, Germany Acquires HUB Organoids Holding B.V., Expands Next-Gen Biology Portfolio
HUB Organoids official news RSS · 行业原文收录 · 来源发布：Mon Jan 06 2025 13:23:34 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 07:03:32 GMT+0000 (Coordinated Universal Time)
Reinforces company’s commitment to differentiated solutions that enable faster and more effective drug development HUB’s organoid offering complements company’s cell culture portfolio of media, reagents, and benchtop ins
Accelerating Single-Cell Deep Learning with scDataset and Tahoe-100M
Tahoe official blog RSS · 行业原文收录 · 来源发布：Wed Jul 16 2025 18:56:30 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 07:03:31 GMT+0000 (Coordinated Universal Time)
As single-cell technologies scale, biology is entering a new era—one where the volume and complexity of data now rival those in fields like computer vision and natural language processing. Among the most powerful advance
晶泰AI4S助力艾滋病治愈获关键进展：候选药物高效提名PCC
XtalPi official Chinese RSS · 行业原文收录 · 来源发布：Tue Sep 22 2026 08:39:29 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 05:44:17 GMT+0000 (Coordinated Universal Time)
近日，晶泰科技 （2228.HK）孵化企业艾玮泰在 HIV （艾滋病） 药物研发上取得新进展， 其围绕 HIV 关键靶点开发的长效治疗项目已确定临床前候选药物（PCC）。 这一进展把针对 HIV 关键靶点的结构认知落地为真实的药物研发成果，有望帮助患者摆脱长期服药的现状，也为探索艾滋病彻底治愈带来新的可能。 这一成果充分展现了结构研究与 AI 药物设计协同的价值：依托靶点结构信息开展定向筛选，提升实验的针对性，并结合实验反馈迭代优化分子
从AI预测到干湿闭环：AI for Science 正在跨越临界点
XtalPi official Chinese RSS · 行业原文收录 · 来源发布：Wed Oct 07 2026 03:30:18 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 05:44:17 GMT+0000 (Coordinated Universal Time)
科学哲学家卡尔·波普尔认为， 科学在猜想与反驳中向前发展 。提出一个新想法只是开始，接下来还得看它能否经得住检验。 如今，AI 让提出假设变得越来越快。候选药物分子、新材料结构，模型可以在短时间内给出大量方案。但在实验室里，确认它们是否有效，仍可能需要数周甚至数月。 AI 正在快速重构科研的上半场，验证能力渐渐成了卡住科研进度的新瓶颈 。这道难题，该如何解答？ 数字世界假设正在变得空前便利 MIT FutureTech 与 Google
晶泰向美国FDA提交 IND申请，AI + 机器人加速创新药物迈向临床
XtalPi official Chinese RSS · 行业原文收录 · 来源发布：Thu Sep 24 2026 09:02:06 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 05:44:17 GMT+0000 (Coordinated Universal Time)
晶泰科技（2228.HK）今日宣布，其自主研发的肠道限制性高选择性pan-TRK抑制剂KQTD-126已完成临床前研究， 并已向美国食品药品监督管理局（FDA）提交新药临床试验（IND）申请 。 这款抑制剂主要用于治疗肠易激综合征（IBS）及炎症性肠病（IBD）相关慢性肠道疼痛。有望为长期受慢性肠道疼痛困扰的患者提供兼顾疗效与安全性的新选择，也为“高活性、高选择性与组织靶向性难以兼得”这一药物设计经典难题提供了新的解题思路。 这一成果充
晶泰生发管线进入 IND-enabling 阶段：以极低浓度，解锁温和高效生发新可能
XtalPi official Chinese RSS · 行业原文收录 · 来源发布：Fri Oct 02 2026 02:52:02 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 05:44:17 GMT+0000 (Coordinated Universal Time)
晶泰科技（ 2228.HK ）今日宣布，其面向脱发治疗的创新药管线正式进入 IND-enabling（临床试验申请前准备）研究阶段。围绕候选分子的药效、安全性、成药性及 CMC 等关键要素的系统研究已经展开，为临床试验申请奠定基础。 据国家卫健委此前发布的数据，我国脱发人群已超过 2.5 亿，平均每 6 人中就有 1 人受脱发困扰。更值得关注的是，脱发正在明显年轻化——越来越多的 90 后、甚至 00 后，在人生早期阶段就开始面临发际线
寻找下一个“十亿美金分子”科学创业大赛：XtalPi Science，高校年轻人的第一个创业合伙人
XtalPi official Chinese RSS · 行业原文收录 · 来源发布：Tue Sep 29 2026 07:54:08 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 05:44:17 GMT+0000 (Coordinated Universal Time)
符合要求的参赛团队将获得 XtalPi Science 启动 Token 支持。 经过实验验证并进入临床转化的优秀分子，有机会获得超亿元级现金投资。 近日，哈佛大学计算生物学博士 Douglas Yao 因在自家车库中借助 AI 和实验机器人推进候选药物研发，引发了广泛关注。 过去需要团队、实验室和大量专业工具才能完成的部分科研工作，正在被 AI 和自动化工具重新组织。一个科学想法，也开始有机会被更快地设计、验证，并继续向前推进。 一个
AlphaFold ‘goes viral’: database adds protein complexes of common viruses
Crossref REST API · 学术索引收录 · 来源发布：Thu Sep 24 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 11:07:46 GMT+0000 (Coordinated Universal Time)
AlphaFold ‘goes viral’: database adds protein complexes of common viruses
Sampling protein language models for functional protein design
Crossref REST API · 学术索引收录 · 来源发布：日期未提供 · 本站收录：Thu Oct 08 2026 09:31:31 GMT+0000 (Coordinated Universal Time)
Sampling protein language models for functional protein design
Robust out-of-distribution prediction of Buchwald–Hartwig reactions
Crossref REST API · 学术索引收录 · 来源发布：Mon Aug 10 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:29:04 GMT+0000 (Coordinated Universal Time)
Abstract The Buchwald–Hartwig cross-coupling is a cornerstone of modern pharmaceutical synthesis, yet predictive modeling of its outcomes remains constrained by data quality and chemical space coverage. Electronic labora
Multistate and functional protein design using RoseTTAFold sequence space diffusion
Crossref REST API · 学术索引收录 · 来源发布：Wed Sep 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:21:33 GMT+0000 (Coordinated Universal Time)
Abstract Protein denoising diffusion probabilistic models are used for the de novo generation of protein backbones but are limited in their ability to guide generation of proteins with sequence-specific attributes and fu
Atomically accurate de novo design of antibodies with RFdiffusion
Crossref REST API · 学术索引收录 · 来源发布：Wed Nov 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:15:50 GMT+0000 (Coordinated Universal Time)
Abstract Despite the central role of antibodies in modern medicine, no method currently exists to design novel, epitope-specific antibodies entirely in silico. Instead, antibody discovery currently relies on immunization
De novo designed proteins neutralize lethal snake venom toxins
Crossref REST API · 学术索引收录 · 来源发布：Wed Jan 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:15:48 GMT+0000 (Coordinated Universal Time)
Abstract Snakebite envenoming remains a devastating and neglected tropical disease, claiming over 100,000 lives annually and causing severe complications and long-lasting disabilities for many more 1,2 . Three-finger tox
Engineering human multi-organ tissue chip niches for drug absorption, distribution, metabolism, excretion and toxicity prediction.
PubMed / NCBI E-utilities · 学术索引收录 · 来源发布：Mon Oct 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:09:29 GMT+0000 (Coordinated Universal Time)
Predicting human drug responses in vitro remains a central challenge in drug development. Animal models have shown limited accuracy in recapitulating human drug absorption, distribution, metabolism, excretion and toxicit
CytoVI: deep generative modeling of antibody-based single cell data.
PubMed / NCBI E-utilities · 学术索引收录 · 来源发布：Wed Sep 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:09:22 GMT+0000 (Coordinated Universal Time)
Antibody-based single-cell technologies, such as flow cytometry, mass cytometry and CITE-seq, have become widely used in clinical diagnostics and basic research; however, their analysis is complicated by technical noise,
FLIGHTED: Inferring fitness landscapes from noisy high-throughput experimental data.
PubMed / NCBI E-utilities · 学术索引收录 · 来源发布：Fri Oct 02 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:09:22 GMT+0000 (Coordinated Universal Time)
Machine learning (ML) for protein design requires large protein fitness datasets generated by high-throughput experiments for training and benchmarking models. However, most models do not account for experimental noise i
Function-preserving watermarking of AI-generated proteins.
PubMed / NCBI E-utilities · 学术索引收录 · 来源发布：Wed Sep 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:09:22 GMT+0000 (Coordinated Universal Time)
Generative artificial intelligence (AI) models are revolutionizing biology, with tools such as AlphaFold 3 and protein design models accelerating breakthroughs in protein structure prediction and the creation of new func
Machine learning for functional protein design.
Europe PMC REST API · 学术索引收录 · 来源发布：Thu Feb 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:43 GMT+0000 (Coordinated Universal Time)
Recent breakthroughs in AI coupled with the rapid accumulation of protein sequence and structure data have radically transformed computational protein design. New methods promise to escape the constraints of natural and
A Generative Neural Network for Maximizing Fitness and Diversity of Synthetic DNA and Protein Sequences.
Europe PMC REST API · 学术索引收录 · 来源发布：Thu Jun 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:43 GMT+0000 (Coordinated Universal Time)
Engineering gene and protein sequences with defined functional properties is a major goal of synthetic biology. Deep neural network models, together with gradient ascent-style optimization, show promise for sequence desi
AI-enhanced adaptive virtual screening of large libraries for ligand discovery.
Europe PMC REST API · 学术索引收录 · 来源发布：Tue Sep 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:43 GMT+0000 (Coordinated Universal Time)
Ultralarge virtual screenings (ULVSs) evaluate billions of molecules for drug discovery but face cost, flexibility and scalability limits. We introduce AdaptiveFlow, an open-source platform that makes ULVSs more accessib
Artificial intelligence for natural product drug discovery.
Europe PMC REST API · 学术索引收录 · 来源发布：Mon Sep 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:43 GMT+0000 (Coordinated Universal Time)
Developments in computational omics technologies have provided new means to access the hidden diversity of natural products, unearthing new potential for drug discovery. In parallel, artificial intelligence approaches su
The Virtual Biotech: A multi-agent AI framework for therapeutic discovery and development.
PubMed / NCBI E-utilities · 学术索引收录 · 来源发布：Thu Sep 17 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:33 GMT+0000 (Coordinated Universal Time)
Drug development requires evidence integration across biological scales and modalities, but relevant tools are fragmented. We introduce the Virtual Biotech, an organization of artificial intelligence (AI) agents modeled
Binding and sensing diverse small molecules using shape-complementary pseudocycles.
Europe PMC REST API · 学术索引收录 · 来源发布：Thu Jul 18 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:29 GMT+0000 (Coordinated Universal Time)
We describe an approach for designing high-affinity small molecule-binding proteins poised for downstream sensing. We use deep learning-generated pseudocycles with repeating structural units surrounding central binding p
Predicting the conformational flexibility of antibody and T cell receptor complementarity-determining regions.
Europe PMC REST API · 学术索引收录 · 来源发布：Thu Oct 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:13 GMT+0000 (Coordinated Universal Time)
Many proteins are highly flexible and their ability to adapt their shape can be fundamental to their functional properties. For example, the flexibility of antibody complementarity-determining region (CDR) loops influenc
How to build the virtual cell with artificial intelligence: Priorities and opportunities.
Europe PMC REST API · 学术索引收录 · 来源发布：Sun Dec 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:13 GMT+0000 (Coordinated Universal Time)
Cells are essential to understanding health and disease, yet traditional models fall short of modeling and simulating their function and behavior. Advances in AI and omics offer groundbreaking opportunities to create an
Assessing the potential of deep learning for protein-ligand docking.
Europe PMC REST API · 学术索引收录 · 来源发布：Wed Dec 31 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:13 GMT+0000 (Coordinated Universal Time)
The effects of ligand binding on protein structures and their in vivo functions carry numerous implications for modern biomedical research and biotechnology development efforts such as drug discovery. Although several de
Systematic scRNA-seq screens profile neural organoid response to morphogens.
Europe PMC REST API · 学术索引收录 · 来源发布：Mon Dec 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:13 GMT+0000 (Coordinated Universal Time)
Morphogens direct neuroepithelial fates toward discrete regional identities in vivo. Neural organoids provide models for studying neural regionalization through morphogen exposure; however, we lack a comprehensive survey
Deep-learning-based de novo discovery and design of therapeutics that reverse disease-associated transcriptional phenotypes.
Europe PMC REST API · 学术索引收录 · 来源发布：Tue Mar 17 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:13 GMT+0000 (Coordinated Universal Time)
Identifying drugs that reverse disease-associated transcriptomic features has been widely explored for drug repurposing, but its potential for de novo drug discovery remains underexplored. Here, we present gene expressio
Miniaturizing and modifying natural proteins with Raygun.
Europe PMC REST API · 学术索引收录 · 来源发布：Wed Jul 29 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:13 GMT+0000 (Coordinated Universal Time)
Proteins have evolved over billions of years through coordinated substitutions, insertions and deletions, yet computational protein design cannot fully replicate nature's ability to engineer new proteins from existing te
Sparks of function by de novo protein design.
Europe PMC REST API · 学术索引收录 · 来源发布：Thu Feb 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:13 GMT+0000 (Coordinated Universal Time)
Information in proteins flows from sequence to structure to function, with each step causally driven by the preceding one. Protein design is founded on inverting this process: specify a desired function, design a structu
A deep generative model for deciphering cellular dynamics and in silico drug discovery in complex diseases.
Europe PMC REST API · 学术索引收录 · 来源发布：Fri Jun 20 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:13 GMT+0000 (Coordinated Universal Time)
Human diseases are characterized by intricate cellular dynamics. Single-cell transcriptomics provides critical insights, yet a persistent gap remains in computational tools for detailed disease progression analysis and t
Interpretable spatially aware dimension reduction of spatial transcriptomics with STAMP.
Europe PMC REST API · 学术索引收录 · 来源发布：Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:13 GMT+0000 (Coordinated Universal Time)
Spatial transcriptomics produces high-dimensional gene expression measurements with spatial context. Obtaining a biologically meaningful low-dimensional representation of such data is crucial for effective interpretation
Transitive prediction of small-molecule function through alignment of high-content screening resources.
Europe PMC REST API · 学术索引收录 · 来源发布：Fri Jul 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:13 GMT+0000 (Coordinated Universal Time)
High-content image-based phenotypic screens (HCSs) provide a scalable approach to characterize biological functions of compounds. The widespread adoption of HCS has led to a growing body of available profile datasets. Ho
Structure-based drug design with equivariant diffusion models.
Europe PMC REST API · 学术索引收录 · 来源发布：Mon Dec 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:13 GMT+0000 (Coordinated Universal Time)
Structure-based drug design (SBDD) aims to design small-molecule ligands that bind with high affinity and specificity to pre-determined protein targets. Generative SBDD methods leverage structural data of drugs with thei
Evolution-guided protein design of IscB for persistent epigenome editing in vivo.
Europe PMC REST API · 学术索引收录 · 来源发布：Wed May 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:13 GMT+0000 (Coordinated Universal Time)
Naturally existing enzymes have been adapted for a variety of molecular technologies, with enhancements or modifications to the enzymes introduced to improve the desired function; however, it is difficult to engineer var
MISATO: machine learning dataset of protein-ligand complexes for structure-based drug discovery.
Europe PMC REST API · 学术索引收录 · 来源发布：Fri May 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:13 GMT+0000 (Coordinated Universal Time)
Large language models have greatly enhanced our ability to understand biology and chemistry, yet robust methods for structure-based drug discovery, quantum chemistry and structural biology are still sparse. Precise biomo
Sequence and structural determinants of efficacious de novo chimaeric antigen receptors.
PubMed / NCBI E-utilities · 学术索引收录 · 来源发布：Wed Sep 09 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:08 GMT+0000 (Coordinated Universal Time)
Advances in generative protein design using artificial intelligence (AI) have enabled the rapid development of binders against heterogeneous targets, including tumour-associated antigens. Despite extensive biochemical ch
An operational perturbation proteomics-based virtual cell model.
PubMed / NCBI E-utilities · 学术索引收录 · 来源发布：Wed Sep 09 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:08 GMT+0000 (Coordinated Universal Time)
Artificial intelligence-empowered virtual cell models represent an emerging approach for in silico drug discovery 1-3 , yet most existing approaches lack large-scale, time-resolved perturbation proteomics data and interp
Predicting brain morphogenesis via physics-transfer learning.
PubMed / NCBI E-utilities · 学术索引收录 · 来源发布：Wed Sep 09 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:08 GMT+0000 (Coordinated Universal Time)
Brain morphology emerges from the interplay of genetic programming and mechanical forces, yet its fractal-like folding patterns make quantitative analysis and prediction difficult, especially when labeled data are scarce
4D spatiotemporal landscape of mitochondrial phenotypes across cellular states unlocked through representation learning.
PubMed / NCBI E-utilities · 学术索引收录 · 来源发布：Thu Sep 10 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:08 GMT+0000 (Coordinated Universal Time)
Mitochondria are four-dimensional (4D: x, y, z, and time) organelles essential for cellular function. Characterizing their 4D phenotypic landscape across diverse cellular states requires both 4D imaging and analytical fr
Resolving data bias improves generalization in binding affinity prediction.
Europe PMC REST API · 学术索引收录 · 来源发布：Tue Oct 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:05 GMT+0000 (Coordinated Universal Time)
The field of computational drug design requires accurate scoring functions to predict binding affinities for protein-ligand interactions. However, train-test data leakage between the PDBbind database and the Comparative
Generating 3D Binding Molecules Using Shape-Conditioned Diffusion Models with Guidance.
Europe PMC REST API · 学术索引收录 · 来源发布：Mon May 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:05 GMT+0000 (Coordinated Universal Time)
Drug development is a critical but notoriously resource- and time-consuming process. In this manuscript, we develop a novel generative artificial intelligence (genAI) method DiffSMol to facilitate drug development. DiffS
Multimodal out-of-distribution individual uncertainty quantification enhances binding affinity prediction for polypharmacology.
Europe PMC REST API · 学术索引收录 · 来源发布：Thu Dec 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:05 GMT+0000 (Coordinated Universal Time)
Polypharmacology, a single drug that targets multiple proteins, holds promise for addressing unmet medical needs. Achieving accurate, reliable and scalable predictions of protein-ligand binding affinity across multiple p
Selection and prioritization of candidate combination regimens for the treatment of tuberculosis.
Europe PMC REST API · 学术索引收录 · 来源发布：Wed Feb 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:07:53 GMT+0000 (Coordinated Universal Time)
Accelerated tuberculosis drug discovery has increased the number of plausible multidrug regimens. Testing every drug combination in vivo is impractical, and varied experimental conditions make it challenging to compare r
Structure and evolution-guided design of minimal RNA-guided nucleases.
Europe PMC REST API · 学术索引收录 · 来源发布：Thu Jul 16 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:07:53 GMT+0000 (Coordinated Universal Time)
The design of RNA-guided nucleases with properties not limited by evolution can expand programmable genome-editing capabilities. However, generating diverse multidomain proteins with robust enzymatic properties remains c
Universal pipeline for high-resolution GPCR structure determination.
Europe PMC REST API · 学术索引收录 · 来源发布：Fri Aug 28 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:07:53 GMT+0000 (Coordinated Universal Time)
G protein-coupled receptors (GPCRs) regulate human physiology and are major drug targets. Although cryo-electron microscopy has accelerated GPCR structural biology, inactive-state structures remain difficult because curr
Digitalized organoids: integrated pipeline for high-speed 3D analysis of organoid structures using multilevel segmentation and cellular topology.
Europe PMC REST API · 学术索引收录 · 来源发布：Wed May 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 06:43:58 GMT+0000 (Coordinated Universal Time)
Organoids replicate tissue architecture and function and offer a unique opportunity to explore the impact of external perturbations in vitro. However, conducting large-scale screening procedures to investigate the effect
Cell tracking with accurate error prediction.
Europe PMC REST API · 学术索引收录 · 来源发布：Wed Oct 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 06:39:04 GMT+0000 (Coordinated Universal Time)
Cell tracking is an indispensable tool for studying development by time-lapse imaging. However, existing cell trackers cannot assign confidence to predicted tracks, which prohibits fully automated analysis without manual
CellART: a unified framework for extracting single-cell information from high-resolution spatial transcriptomics.
PubMed / NCBI E-utilities · 学术索引收录 · 来源发布：Mon Oct 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 05:41:45 GMT+0000 (Coordinated Universal Time)
Recent advances in spatial transcriptomics (ST) have achieved subcellular spatial resolution, yet existing platforms either capture sparse transcript counts per spot or measure only a limited number of genes, complicatin